文献速递银屑病与炎症性皮肤病

观察性数据复制随机试验:司库奇尤单抗与乌司奴单抗治疗银屑病的比较效果

Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register.
PubMed 文献 · JAMA Dermatol · 2021-01-01

该研究利用BADBIR注册数据,采用目标试验模拟方法,比较司库奇尤单抗与乌司奴单抗治疗中重度银屑病患者的12个月疗效。共纳入1231例患者(乌司奴单抗917例,司库奇尤单抗314例),主要结局为PASI≤2的风险比和风险差。结果显示司库奇尤单抗在多数分析中优于乌司奴单抗,且效果估计与CLEAR随机试验达到监管一致性。

要点

  • 司库奇尤单抗在12个月时达到PASI≤2的比例高于乌司奴单抗。
  • 倾向评分加权完整案例分析:RR 1.28(95%CI 1.06-1.55),RD 11.9%(1.6-22.1)。
  • 目标试验模拟结果与CLEAR随机试验在监管和估计上一致。

核心结论

  • 在BADBIR注册的中重度银屑病患者中,司库奇尤单抗治疗12个月达到PASI≤2的患者比例高于乌司奴单抗。
  • 目标试验模拟产生的效果估计与CLEAR随机临床试验在监管和估计上一致。

研究设计与样本

  • 比较效果研究,采用目标试验模拟方法,数据来自英国和爱尔兰的多中心纵向药物警戒注册BADBIR,时间范围为2007年11月至2019年8月。
  • 纳入年龄≥18岁、慢性斑块状银屑病、在启动司库奇尤单抗或乌司奴单抗前至少有一次PASI≥12记录的患者。
  • 共纳入1231例患者,其中917例接受乌司奴单抗,314例接受司库奇尤单抗。
  • 采用倾向评分1:1匹配分析和逆概率治疗加权分析。

主要发现

  • 除无应答者插补法外,所有分析均显示司库奇尤单抗在达到PASI≤2的比例上优于乌司奴单抗。
  • 倾向评分加权完整案例分析:RR 1.28(95%CI 1.06-1.55),RD 11.9%(1.6-22.1)。
  • 除无应答者插补法外,所有分析在倾向评分匹配和加权分析中均达到监管一致性。

关键数值与推荐

  • 主要结局为治疗12个月后达到PASI≤2的风险比(RR)和风险差(RD),比较司库奇尤单抗与乌司奴单抗。
  • 缺失结局数据处理方法包括完整案例分析、无应答者插补、末次观测值结转、逆概率删失加权和多重插补。
  • 使用监管和估计一致性指标将本研究效果估计与CLEAR试验进行基准比较。

临床怎么用

  • 在真实世界实践中,司库奇尤单抗在12个月时达到PASI≤2的可能性高于乌司奴单抗,支持其作为中重度银屑病的治疗选择。
  • 目标试验模拟方法可用于比较其他系统治疗,填补随机试验证据空白。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatments for psoriasis may be less effective in everyday practice than in clinical trials. Emulating a target trial using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) can provide treatment effect estimates that are robust and can inform both clinicians and regulatory bodies. OBJECTIVES: To assess the comparative effectiveness of ustekinumab and secukinumab in patients with psoriasis, and to test whether the relative effectiveness estimate of the CLEAR trial, a randomized clinical trial that compared secukinumab with ustekinumab for psoriasis, can be replicated. DESIGN, SETTING, AND PARTICIPANTS: This comparative effectiveness research study used a target trial emulation approach and was performed between November 2007 and August 2019. Data were obtained from BADBIR, a multicenter longitudinal pharmacovigilance register of patients with moderate to severe psoriasis in the United Kingdom and Republic of Ireland. Participants had chronic plaque psoriasis, were 18 years or older, and had at least 1 record of a Psoriasis Area and Severity Index (PASI) of 12 or higher before their initiation to secukinumab or ustekinumab. Propensity score (PS) 1:1 matched analysis and inverse probability treatment weighted analysis were performed. MAIN OUTCOMES AND MEASURES: The primary outcomes were the risk ratio (RR) and the risk difference (RD) for achieving PASI of 2 or lower after 12 months of therapy for secukinumab compared with ustekinumab. Methods to account for missing outcome data were complete case analysis, nonresponder imputation, last observation carried forward, inverse probability of censoring weighting, and multiple imputation. Regulatory and estimate agreement metrics were used to benchmark the effect estimates in this study against those in the CLEAR trial. RESULTS: A total of 1231 patients were included in the analysis, with 917 receiving ustekinumab and 314 receiving secukinumab. Secukinumab was superior to ustekinumab in all analyses, except under the nonresponder imputation method, in the proportion of participants achieving a PASI of 2 or lower (PS-weighted complete case analysis: RR, 1.28 [95% CI, 1.06-1.55]; RD, 11.9% [1.6-22.1]). All analyses, except for nonresponder imputation, reached regulatory agreement in both PS-matching and PS-weighted analyses. CONCLUSIONS AND RELEVANCE: This comparative effectiveness study found that secukinumab resulted in more patients achieving a PASI of 2 or lower after 12 months of therapy compared with ustekinumab in patients with psoriasis. Target trial emulation in this study resulted in regulatory and estimate agreement with the CLEAR randomized clinical trial; further such studies may help fill the evidence gap when comparing other systemic therapies for psoriasis.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Yiu ZZN, Mason KJ, Hampton PJ, et al. Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatol. 2021. PMID: 33263718. doi:10.1001/jamadermatol.2020.4202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。